DEX M74

Drug Profile

DEX M74

Alternative Names: ManNAc; N-acetyl-D-mannosamine

Latest Information Update: 30 Dec 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator New Zealand Pharmaceuticals
  • Developer Escala Therapeutics; Natioanl Institues of Health Clinical Center; National Human Genome Research Institute
  • Class Hexosamines; Small molecules
  • Mechanism of Action Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nonaka distal myopathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nonaka distal myopathy
  • Phase I Kidney disorders

Most Recent Events

  • 11 Dec 2015 Escala Therapeutics plans a phase I trial for Kidney disorders (Fortress Biotech pipeline)
  • 01 Dec 2015 Phase-I clinical trials in Kidney disorders (Treatment-experienced) in USA (PO) (NCT02639260)
  • 25 Aug 2015 New Zealand Pharmaceuticals receives patent allowance for N-acetyl-D-mannosamine in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top